We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

117 hedge funds and large institutions have $547M invested in Neurocrine Biosciences in 2013 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 34 increasing their positions, 43 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

469% more call options, than puts

Call options by funds: $6.31M | Put options by funds: $1.11M

4% less funds holding

Funds holding: 122 → 117 (-5)

19% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 27

20% less capital invested

Capital invested by funds: $680M → $547M (-$133M)

21% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 43

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
117
Holders Change
-5
Holders Change %
-4.1%
% of All Funds
3.4%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
22
Increased
34
Reduced
43
Closed
27
Calls
$6.31M
Puts
$1.11M
Net Calls
+$5.2M
Net Calls Change
-$26K

Top Buyers

1
O
OrbiMed
New York
+$20.1M
2
Millennium Management
Millennium Management
New York
+$7.47M
3
BB
BB Biotech
Switzerland
+$6.8M
4
Franklin Resources
Franklin Resources
California
+$4.84M
5
Invesco
Invesco
Georgia
+$4.13M

Top Sellers

1
Jennison Associates
Jennison Associates
New York
-$18.6M
2
MG
Meditor Group
Bermuda
-$11.9M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$6.84M
4
PC
PointState Capital
New York
-$5.66M
5
VM
VHCP Management
New York
-$5.62M
Name Holding Trade Value Shares
Change 		Change in
Stake
RhumbLine Advisers
51
RhumbLine Advisers
Massachusetts
$654K -$976 -100 -0.1%
NTCOC
52
Northern Trust Company of Connecticut
Connecticut
$634K -$41K -4,200 -6%
Susquehanna International Group
53
Susquehanna International Group
Pennsylvania
$629K +$656K +67,249 New
QF
54
QVT Financial
New York
$593K -$4.65M -476,500 -88%
State Board of Administration of Florida Retirement System
55
State Board of Administration of Florida Retirement System
Florida
$576K – – –
Arrowstreet Capital
56
Arrowstreet Capital
Massachusetts
$564K -$418K -42,881 -42%
Swiss National Bank
57
Swiss National Bank
Switzerland
$555K – – –
MLICM
58
Metropolitan Life Insurance Company (MetLife)
New York
$525K – – –
GPCM
59
Granite Point Capital Management
Massachusetts
$514K +$537K +55,000 New
DY
60
Dowling & Yahnke
California
$495K – – –
NFA
61
Nationwide Fund Advisors
Ohio
$481K -$15.5K -1,588 -3%
Morgan Stanley
62
Morgan Stanley
New York
$467K +$38.9K +3,987 +9%
3NC
63
300 North Capital
California
$454K -$36.1K -3,700 -7%
Zurich Cantonal Bank
64
Zurich Cantonal Bank
Switzerland
$420K – – –
AIG
65
American International Group
New York
$414K -$4.34K -445 -1%
BA
66
BlackRock Advisors
Delaware
$412K +$27.9K +2,863 +7%
HCM
67
Highbridge Capital Management
New York
$406K +$424K +43,452 New
DBG
68
De Burlo Group
Massachusetts
$386K -$72.2K -7,400 -15%
VOYA Investment Management
69
VOYA Investment Management
Georgia
$377K – – –
Citadel Advisors
70
Citadel Advisors
Florida
$374K +$362K +37,106 +1,288%
Connor, Clark & Lunn Investment Management (CC&L)
71
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$364K -$543K -55,600 -60%
DekaBank Deutsche Girozentrale
72
DekaBank Deutsche Girozentrale
Germany
$361K +$9.76K +1,000 +3%
EAM
73
Eventide Asset Management
Massachusetts
$360K +$376K +38,500 New
GH
74
GAM Holding
Switzerland
$346K +$97.6K +10,000 +37%
Public Employees Retirement Association of Colorado
75
Public Employees Retirement Association of Colorado
Colorado
$329K – – –
1 2
3
4 5

NBIX Hedge Fund Activity: Q4 2013 in Review

117 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2013, worth a combined $547M — down 20% from $680M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of NBIX and 22 opened new positions — a net loss of 5 holders — while 43 trimmed existing stakes and 34 added.

The largest buyer was OrbiMed, adding an estimated $20.1M. The largest seller was Jennison Associates, exiting entirely with an estimated $18.6M sold.

  • 117 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2013, down from 122 in Q3 2013.
  • Funds reported $547M of Neurocrine Biosciences stock for Q4 2013, down 20% quarter-over-quarter.
  • 22 funds opened new Neurocrine Biosciences positions in Q4 2013 and 27 closed out, a net change of -5 holders.
  • The largest Neurocrine Biosciences buyer in Q4 2013 was OrbiMed, an estimated $20.1M added.
  • The largest Neurocrine Biosciences seller in Q4 2013 was Jennison Associates, an estimated $18.6M sold.

Based on aggregated 13F filings for Q4 2013.